ATE360000T1 - Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung - Google Patents

Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Info

Publication number
ATE360000T1
ATE360000T1 AT02767010T AT02767010T ATE360000T1 AT E360000 T1 ATE360000 T1 AT E360000T1 AT 02767010 T AT02767010 T AT 02767010T AT 02767010 T AT02767010 T AT 02767010T AT E360000 T1 ATE360000 T1 AT E360000T1
Authority
AT
Austria
Prior art keywords
dihydroxy
vitamin
alpha
sub
oxime
Prior art date
Application number
AT02767010T
Other languages
English (en)
Inventor
Gary H Posner
Jay A White
Glenville Jones
Bethany Halford
Mehmet Kahraman
Heung Bae Jeon
Original Assignee
Univ Johns Hopkins
Cytochroma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Cytochroma Inc filed Critical Univ Johns Hopkins
Application granted granted Critical
Publication of ATE360000T1 publication Critical patent/ATE360000T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C401/00—Irradiation products of cholesterol or its derivatives; Vitamin D derivatives, 9,10-seco cyclopenta[a]phenanthrene or analogues obtained by chemical preparation without irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02767010T 2001-10-12 2002-10-11 Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung ATE360000T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32842801P 2001-10-12 2001-10-12

Publications (1)

Publication Number Publication Date
ATE360000T1 true ATE360000T1 (de) 2007-05-15

Family

ID=23280940

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02767010T ATE360000T1 (de) 2001-10-12 2002-10-11 Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung

Country Status (11)

Country Link
US (1) US6982258B2 (de)
EP (1) EP1436257B1 (de)
JP (1) JP4436674B2 (de)
AT (1) ATE360000T1 (de)
CA (1) CA2463505C (de)
CY (1) CY1106638T1 (de)
DE (1) DE60219655T2 (de)
DK (1) DK1436257T3 (de)
ES (1) ES2283593T3 (de)
PT (1) PT1436257E (de)
WO (1) WO2003031400A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087350A (en) * 1997-08-29 2000-07-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of pretreatment chemicals to enhance efficacy of cytotoxic agents
US20050059641A1 (en) * 2003-06-17 2005-03-17 Aphios Corporation Compositions and methods for treating and preventing cancer using analogs of vitamin D
US20050192255A1 (en) * 2003-07-30 2005-09-01 Jin Tian Use of Vitamin Ds or Vitamin D analogs to treat cardiovascular disease
MXPA06013029A (es) * 2004-05-10 2007-02-12 Novacea Inc Prevencion de la restenosis arterial con compuestos de vitamina d activos.
WO2006032299A1 (en) * 2004-09-24 2006-03-30 Susanna Miettinen Use of inhibitors of 24-hydroxylase in the treatment of cancer
WO2006074227A2 (en) * 2005-01-04 2006-07-13 Johns Hopkins University HIGHLY ANTIPROLIFERATIVE, LOW-CALCEMIC, ANALOGS OF THE HORMONE 1α, 25-DIHYDROXYVITAMIN D3 WITH CARBONYL SIDE CHAINS
JP5449767B2 (ja) * 2005-04-25 2014-03-19 サイトクロマ インコーポレイテッド １α，２５−ジヒドロキシビタミンＤ３の低血漿カルシウム上昇性１６，２３−ジエン−２５−オキシムアナログ
EP1945185B1 (de) * 2005-10-12 2016-02-03 Proventiv Therapeutics, LLC Verfahren und artikel zur behandlung von 25-hydroxyvitamin-d-insuffizienz und mangel
DK3095447T3 (da) 2006-02-03 2022-01-31 Opko Renal Llc Behandling af vitamin d-insufficiens og -mangel med 25-hydroxyvitamin d2 og 25-hydroxyvitamin d3
EP2037936B1 (de) 2006-06-21 2014-06-11 Proventiv Therapeutics, LLC Verfahren zur behandlung und vorbeugung von sekundärem hyperparathyroidismus
AU2008242711A1 (en) * 2007-04-18 2008-10-30 Johns Hopkins University Low calcemic, highly antiproliferative, analogs of calcitriol
JP5444212B2 (ja) * 2007-04-25 2014-03-19 シトクロマ インコーポレイテッド ビタミンｄ不足および欠乏症の治療方法
CA2684778C (en) * 2007-04-25 2017-09-05 Cytochroma Inc. Methods and compounds for vitamin d therapy
PL3542792T3 (pl) 2007-04-25 2023-11-20 Eirgen Pharma Ltd. 25-hydroksywitamina d o kontrolowanym uwalnianiu
EP3225243A1 (de) 2007-04-25 2017-10-04 Opko Renal, LLC Verfahren zur sicheren und effektiven behandlung und vorbeugung von sekundärem hyperparathyroidismus für chronische nierenerkrankung
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
GB2470700B (en) 2008-03-25 2012-08-08 Univ Maryland C-17 heteroaryl steroidal CYP17 inhibitors
ES2593356T3 (es) 2008-04-02 2016-12-07 Opko Ireland Global Holdings, Ltd. Métodos, composiciones, usos y kits útiles para la deficiencia de la vitamina D y trastornos relacionados
CN102686600A (zh) 2009-02-05 2012-09-19 托凯药业股份有限公司 甾体cyp17抑制剂/抗雄激素物质的新型药物前体
US20100227414A1 (en) * 2009-03-05 2010-09-09 Trex Enterprises Corp. Affinity capture mass spectroscopy with a porous silicon biosensor
WO2011088209A2 (en) 2010-01-13 2011-07-21 Cytochroma Inc. 1-deoxy analogs of vitamin d-related compounds
US11672809B2 (en) 2010-03-29 2023-06-13 Eirgen Pharma Ltd. Methods and compositions for reducing parathyroid levels
CA2904170A1 (en) 2013-03-14 2014-09-25 University Of Maryland, Baltimore Androgen receptor down-regulating agents and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
CA2920317A1 (en) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
CN104557647B (zh) * 2015-01-13 2016-07-06 南京理工大学 维生素d肟类衍生物、合成方法及其应用
CN104945296B (zh) * 2015-06-09 2016-08-24 南京理工大学 一类芳香醛腙修饰的维生素d2衍生物、合成及其应用
CR20180510A (es) 2016-03-28 2019-05-15 Opko Ireland Global Holdings Ltd Método de tratamiento con vitamina d
CN117003679A (zh) * 2022-04-29 2023-11-07 南澳大利亚大学 新型抑制剂化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481198A (en) * 1984-02-13 1984-11-06 Wisconsin Alumni Research Foundation Vitamin D metabolism inhibitor
GB9623569D0 (en) * 1996-11-13 1997-01-08 Immunodiagnostic Systems Ltd Vitamin D immumoassay systems

Also Published As

Publication number Publication date
DK1436257T3 (da) 2007-06-25
US6982258B2 (en) 2006-01-03
ES2283593T3 (es) 2007-11-01
EP1436257A1 (de) 2004-07-14
EP1436257B1 (de) 2007-04-18
WO2003031400A1 (en) 2003-04-17
DE60219655D1 (de) 2007-05-31
JP2005536444A (ja) 2005-12-02
US20030171342A1 (en) 2003-09-11
CA2463505A1 (en) 2003-04-17
JP4436674B2 (ja) 2010-03-24
DE60219655T2 (de) 2007-12-27
CA2463505C (en) 2011-07-12
PT1436257E (pt) 2007-05-31
CY1106638T1 (el) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE360000T1 (de) Oxim-analoga von 1-alpha,25-dihydroxy-vitamin-d3 mit geringer calcemischer wirkung
AR026173A1 (es) Inhibidores de neuraminidasas.
EA200301216A1 (ru) Замещенные хинуклидинами мультициклические гетероарилы для лечения заболевания
NO20031687D0 (no) Veksthormonsekretagoger
BRPI0410081A (pt) composto, composição farmacêutica, método de tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
ATE232873T1 (de) Phosphonsaürederivate als ptp-1b-inhibitoren
CO4910163A1 (es) Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas
BR0212733A (pt) Composto, composição farmacêutica, uso de um composto, e, método para o tratamento de um distúrbio afetivo
BRPI0410117A (pt) composto, composição farmacêutica, método para o tratamento de uma doença ou condição mediada por jak3, e, processo para a preparação de um composto
SE0101675D0 (sv) Novel composition
NO331013B1 (no) Nye forbindelser som er anti-inflammasjons, immunomodulerende og anti-proliferative midler, anvendelse av forbindelsene samt farmasoytisk preparat
FI956119A (fi) Fenyyliheterosyklejä syklo-oksigenaasi-2-inhibiittoreina
BRPI0410630A (pt) antagonista de nk1
DE60223923D1 (de) Prodrugs von gaba-analoga, zusammensetzungen und ihre verwendungszwecke
BR0112030A (pt) Novos compostos que possuem atividade antibacteriana, antifúngica ou antitumor
UY27548A1 (es) Sales de ácido succínico de 5,7,14-triazatetraciclo (10.3.1.02.11.04,9) exadeca-2 (11),3,5,7,9-pentaeno y composiciones farmacéuticas
ATE543796T1 (de) 24-sulfoximine vitamin d3 derivate
NO20050270L (no) Nye forbindelser, deres anvendelse og fremstilling
FR2757857B1 (fr) Diselenures et selenosulfures aromatiques, leur preparation et leurs utilisations, notamment therapeutiques
ATE238986T1 (de) 1,3-dihydroxy-20,20-dialkyl-vitamin d3 analoga
DE60015508T2 (de) C-16 ungesätigte fp-selektive prostaglandin analoge
ATE443044T1 (de) Tace inhibitoren
TR200503401T1 (tr) Kuetiapin (Quetiapine) Fumarat'ın yeni polimorfları
DE60001433D1 (de) Alpha, beta-ungesättigte Ketone
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1436257

Country of ref document: EP